Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ketoprofen
Drug ID BADD_D01231
Description Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Indications and Usage For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Marketing Status Prescription; Discontinued
ATC Code M01AE03; M02AA10
DrugBank ID DB01009
KEGG ID D00132
MeSH ID D007660
PubChem ID 3825
TTD Drug ID D0W9WF
NDC Product Code 49452-3917; 68981-031; 82348-102; 0276-0504; 12660-0006; 69336-127; 12854-516; 43235-0010; 63275-9996; 51927-0057; 76465-0001; 51927-0025; 51552-0307; 63187-018; 38779-0078; 51927-0231; 0395-8056; 45865-485; 38779-3039; 49452-3924; 0378-8200; 79572-019; 51604-0011
Synonyms Ketoprofen | Benzoylhydratropic Acid | 2-(3-Benzoylphenyl)propionic Acid | Profenid | Alrheumum | Orudis | 19,583 RP | RP, 19,583 | RP-19583 | RP 19583 | RP19583 | Alrheumat
Chemical Information
Molecular Formula C16H14O3
CAS Registry Number 22071-15-4
SMILES CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Gastrointestinal toxicityTumor necrosis factorP01375T2017811991627; 11131303; 11930903; 11230998
Gastrointestinal toxicityGlutathione reductase, mitochondrialP00390T3080311991627; 11131303; 11930903; 11230998
Toxic dilatation of intestineTumor necrosis factorP01375T2017811991627; 11131303; 11930903; 11230998
Toxic dilatation of intestineGlutathione reductase, mitochondrialP00390T3080311991627; 11131303; 11930903; 11230998
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.0040.008278%
Dysphoria19.04.02.004--Not Available
Dyspnoea22.02.01.004; 02.01.03.0020.091057%
Dyspnoea exertional22.02.01.005; 02.01.03.0030.008278%Not Available
Eczema23.03.04.006--
Endocarditis11.01.16.001; 02.09.01.0010.002159%
Eosinophilia01.02.04.0010.008278%
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.0010.103473%Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye pain06.08.03.002--
Eyelid oedema10.01.05.001; 06.04.04.004; 23.04.01.0030.049667%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.028973%
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Food interaction08.06.03.0020.016556%Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.020695%
Gastric ulcer07.04.03.0020.020695%
Gastric ulcer haemorrhage07.04.03.005; 24.07.02.0030.008278%Not Available
Gastritis07.08.02.0010.004319%
Gastritis erosive07.04.03.0030.024834%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal pain07.01.05.005--
Gastrointestinal perforation07.04.04.001--Not Available
Generalised tonic-clonic seizure17.12.01.0020.024834%Not Available
Glossodynia07.14.02.001--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages